Abstract：
Everolimus is an orally administered mechanistic target of rapamycin inhibitor in solid-organ transplant patients. In addition to the common adverse side effects of this treatment, such as hyperlipidemia, rash, stomatitis, anorexia, diarrhea, anemia, thrombocytopenia, and leukopenia, pulmonary toxicity is also an important adverse side effect. Although pulmonary toxicity due to everolimus has been reported mostly as pneumonitis, cases of pleural effusion due to everolimus have also been reported rarely. Chylothorax is defined as the accumulation of lymphatic fluid in the pleural space. It may develop secondary to trauma or malignancy. In this case report, we present a patient with chylothorax after everolimus treatment.
摘要：
依维莫司是实体器官移植患者口服雷帕霉素抑制剂的机制靶标。除了这种治疗的常见副作用外，如高脂血症，皮疹,口腔炎,厌食症,腹泻,贫血,血小板减少症,和白细胞减少症,肺毒性也是重要的不良副作用。尽管依维莫司导致的肺毒性主要被报道为肺炎，依维莫司引起的胸腔积液也很少报道。乳糜胸定义为胸膜腔中淋巴液的积聚。它可能继发于创伤或恶性肿瘤。在这个案例报告中,我们介绍了一名依维莫司治疗后乳糜胸患者。
